Navigation Links
Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
Date:5/10/2011

SAN FRANCISCO, May 10, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Helix BioPharma Corporation (AMEX: HBP, TSX: HBP) ("the Company") with a twelve month target price of $6.20. Ross Silver, Principal Analyst at Vista Partners stated, "The Company is developing products for the treatment and prevention of cancer. The first and most advanced, Interferon alpha-2b, is a potent immuno-modulatory drug compound that has been formulated as a topical cream ("TIFNα2b") using Helix's unique, patented Biphasix™ platform technology which is intended to resolve low-grade cervical intraepithelial neoplasia grade 1 or 2 ("CIN 1 or 2") lesions. We believe TIFNα2b, if approved, could have revenues in excess of $500M globally, given the fact that the prospective market size is considerable, with approximately 1.3 million new cases of low-grade cervical lesions diagnosed annually each year in the U.S. alone today for which there are no approved pharmaceutical therapies." Mr. Silver concludes, "The Company's L-DOS47 is the first targeted therapeutic immunoconjugate under development based upon Helix's DOS47 technology. Helix's L-DOS47 is a new drug in development that is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer ("NSCLC")."

To download a FREE copy of the Helix BioPharma Corporation research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's p
'/>"/>

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
3. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
7. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 The board of directors ... ) has declared a dividend for the third quarter ... stock. The dividend is payable September ... of business on August 15, 2013. Lilly, ... of pharmaceutical products by applying the latest research from ...
(Date:6/18/2013)... Today, Wall Street Reports announced new research reports ... Management Associates Inc. (NYSE: HMA ), IDEXX Laboratories, ... ISIS ), and Trius Therapeutics Inc. (NASDAQ: TSRX). ... including full price targets, industry analysis and analyst ratings - ... Report On June 7, 2013, Gilead Sciences Inc. ...
(Date:6/18/2013)... And EMERYVILLE, Calif. , ... presented final results today from a Phase 2/3 ... capsules demonstrating a statistically significant improvement in levodopa-induced ... at week 8 versus placebo in the Unified ... extended-release formulation of amantadine intended for once-nightly administration ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6
... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
(Date:6/18/2013)... The world,s first computer guided fitness training system ... of the three winners of the LeWeb,13 London ... , The startup company, Genetrainer, building on ... PhD graduate, Ralph Pethica and Julian Gough, Professor ... Science, was selected from over 350 startups to ...
(Date:6/18/2013)... June 18, 2013 On June 12th, ... everything about medical marijuana in Canada . ... republish the new Canadian Marijuana for Medical Purposes Regulation ... department of Health Canada. , The Canabud.ca website is ... rapidly growing industry. “As medical marijuana becomes more ...
(Date:6/18/2013)... GA (PRWEB) June 18, 2013 Dr. ... of the Atlanta Vision Institute, is pleased to announce ... next generation of Intralase LASIK equipment, the iFS™ Advanced ... only LASIK practice in Atlanta to offer its patients ... Ashraf is giving his patients a complimentary upgrade to ...
(Date:6/18/2013)... 2013 The Skin and Vein Center ... public on July 9 from 2 p.m. to 5 p.m. ... with the doctor or a nurse, who will give the ... or nurse will inform the patient of the health of ... available for varicose and spider veins. , As part of ...
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 Visitors to New ... a spa promotion from the famed JW Marriott Essex House ... New York City for business or pleasure, guests can take a ... rejuvenating day surrounded by serenity at The Spa at Essex House. ... at the Central Park hotel starting at $379 per night plus ...
Breaking Medicine News(10 mins):Health News:Atlanta LASIK Surgeon Offers New LASIK Technology 2Health News:Kansas City Dermatologists at The Skin and Vein Center Offer Complimentary Vein Screening on July 9 2Health News:New Spa Deal From JW Marriott Essex House New York Will Delight, Relax Visitors 2Health News:New Spa Deal From JW Marriott Essex House New York Will Delight, Relax Visitors 3
... Johns Hopkins University School of Medicine have identified a ... novel autoantibody specificity that makes them potential candidates for ... September issue of Arthritis & Rheumatism , a ... Myopathy is a term used to describe muscle disease. ...
... Aug. 19 (HealthDay News)-- There were no smiles on the faces ... waiting on line for help from the Oregon Employment Department were ... lecture from a middle-aged woman, who leaned in close and whispered ... a lot of unhappy, stressed people here." At rows of ...
... the mainstream media has led many researchers to study ... have indicated that there is a link between exposure ... of sexual activity among teens. However, a study led ... Published this month in the online version of ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. ... eggs has sickened more than 250 people and led to ... news reports. The outbreak, which apparently began in May, ... and Prevention said. On Aug. 13, the CDC said: ...
... School of Medicine in Baltimore have developed a novel ... treatment for ventricular tachycardia, a potentially life-threatening heart rhythm ... The new approach couples CT (computed tomography) images with ... the heart that produce arrhythmias. The results of a ...
... Center in Israel have determined that the use ... outcome for patients undergoing percutaneous coronary intervention (PCI), ... appear in the September issue of Catheterization ... Wiley-Blackwell on behalf of The Society for Cardiovascular ...
Cached Medicine News:Health News:Novel autoantibodies identified in patients with necrotizing myopathy 2Health News:Novel autoantibodies identified in patients with necrotizing myopathy 3Health News:Jobless and Stressed but Holding Out Hope 2Health News:For teens, early sex and media exposure not linked 2Health News:Nationwide Egg Recall Underway 2Health News:Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder 2Health News:Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder 3Health News:Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder 4Health News:Drug-eluting stents confirmed safe, effective for long-term use 2
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
... take their eyes for granted. Like ... eyes need proper nutrition and care ... vision as you age. In fact, ... to maintaining and preserving eye health ...
... The herbal extracts, vitamins, minerals, ... increases circulation to ocular tissue, ... healthy function of the lens ... This formula is optimized to ...
Online Unity Interlaboratory QC Data Management...
Medicine Products: